Investor Presentaiton

EM, Europe and API Emerging Markets $ Mn 55 -17% 45 Q3 FY 19 Q3 FY20 Strengthening portfolio offering in key markets: ☐ The quarter saw the commercialization of products in the market for our partnership with Novartis in Australia and Sri Lanka Progress on the Biosimilar pipeline on target Investor Presentation: Q3FY20 $ Mn Europe 22 27 27 Q3 FY19 Q3 FY20 Strong performance in key DTM1 markets ☐ Overall FPSM UK market share at 15% as per ePACT Oct data ☐ $ Mn ΑΡΙ Cipla 25 23 22 7% 20 25 15 10 5 0 Q3 FY 19 Q3 FY20 Performance in key accounts drives overall growth for the quarter Momentum continues in Seedings & Lock-ins world wide to build future pipeline 1. Direct-to-Market 11

View entire presentation